Combination of Statin and Ezetimibe Versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence Among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study

Overview

Journal J Lipid Atheroscler

Date 2021 Oct 8

PMID 34621701

Citations 3

Authors

You-Bin Lee

Bongsung Kim

Kyungdo Han

Jung A Kim

Eun Roh

So-Hyeon Hong

Kyung Mook Choi

Sei Hyun Baik

Hye Jin Yoo

Affiliations

Soon will be listed here.

Abstract

Objective: We investigated the effects of statin-ezetimibe combination therapy compared with statin-only treatment on the hazard of incident type 2 diabetes (T2D), myocardial infarction (MI), and stroke among adults with impaired fasting glucose (IFG) in a real-world setting.

Methods: The Korean National Health Insurance Service datasets from 2002 to 2017 were used for this propensity-matched nationwide cohort study. Among 56,633 IFG patients without baseline cardiovascular disease (CVD) and/or T2D who initiated statin therapy with or without ezetimibe, 1,155 with statin-ezetimibe combination therapy were matched based on a propensity score at a 1:5 ratio with 5,775 patients who received statin monotherapy. The hazards of T2D, MI, and stroke were compared between these treatment groups.

Results: The incidence rate per 1,000 person-years was 19.62 (statin monotherapy group) and 21.02 (combined treatment group) for T2D, 1.53 (statin monotherapy group) and 1.70 (combined treatment group) for MI, and 1.99 (statin monotherapy group) and 2.06 (combined treatment group) for stroke. The hazards of T2D, MI, and stroke were not significantly different between the statin monotherapy group and the statin-ezetimibe combination therapy group.

Conclusion: The combination of ezetimibe in addition to statin treatment was not associated with a significantly different risk of T2D and CVDs compared with statin monotherapy in Korean adults with IFG.

Citing Articles

Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study.

Noh J, Moon M, Rhee E, Park S, Kim H, Kim B Diabetes Metab J. 2023; 47(1):59-71.

PMID: 36727164 PMC: 9925149. DOI: 10.4093/dmj.2021.0320.

Statins and Clinical Outcomes in Patients With Low to Moderate Risk but With Non-obstructive Carotid Plaques: The SCOPE-CP Study.

Yoon M, Lee C, Park S, Lee S Korean Circ J. 2022; 52(12):890-900.

PMID: 36478652 PMC: 9742388. DOI: 10.4070/kcj.2022.0154.

Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism.

Gonzalez-Lleo A, Sanchez-Hernandez R, Boronat M, Wagner A Nutrients. 2022; 14(7).

PMID: 35406116 PMC: 9002616. DOI: 10.3390/nu14071503.

References

Jung C, Son J, Kang S, Kim W, Kim H, Kim H . Diabetes Fact Sheets in Korea, 2020: An Appraisal of Current Status. Diabetes Metab J. 2021; 45(1):1-10. PMC: 7850879. DOI: 10.4093/dmj.2020.0254. View

Kim J, Lee H, Lee K . Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovasc Diabetol. 2018; 17(1):155. PMC: 6280428. DOI: 10.1186/s12933-018-0799-4. View

Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375(9716):735-42. DOI: 10.1016/S0140-6736(09)61965-6. View

Chang E, Kim L, Choi J, Park S, Rhee E, Lee W . Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015; 64(5):633-41. DOI: 10.1016/j.metabol.2015.02.001. View

Rajpathak S . Intensive statin therapy, compared with moderate dose, increases risk of new onset diabetes but decreases risk of cardiovascular events. Evid Based Med. 2011; 17(2):55-6. DOI: 10.1136/ebm.2011.100198. View

Lee Y, Han K, Kim B, Jun J, Lee S, Ahn J . Risk of end-stage renal disease from chronic kidney disease defined by decreased glomerular filtration rate in type 1 diabetes: A comparison with type 2 diabetes and the effect of metabolic syndrome. Diabetes Metab Res Rev. 2019; 35(8):e3197. DOI: 10.1002/dmrr.3197. View

Lee Y, Lee J, Hong S, Kim J, Roh E, Yoo H . Optimal blood pressure for patients with chronic kidney disease: a nationwide population-based cohort study. Sci Rep. 2021; 11(1):1538. PMC: 7810974. DOI: 10.1038/s41598-021-81328-y. View

Nakamura A, Sato K, Kanazawa M, Kondo M, Endo H, Takahashi T . Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart Vessels. 2018; 34(6):916-925. PMC: 6531627. DOI: 10.1007/s00380-018-1319-x. View

Lee Y, Kim D, Roh E, Hong S, Kim J, Yoo H . Variability in estimated glomerular filtration rate and the incidence of type 2 diabetes: a nationwide population-based study. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7202740. DOI: 10.1136/bmjdrc-2020-001187. View

10.

Kim M, Han K, Koh E, Kim E, Lee M, Nam G . Blood Pressure and Development of Cardiovascular Disease in Koreans With Type 2 Diabetes Mellitus. Hypertension. 2019; 73(2):319-326. View

11.

Seong S, Kim Y, Khang Y, Park J, Kang H, Lee H . Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016; 46(3):799-800. PMC: 5837262. DOI: 10.1093/ije/dyw253. View

12.

Noh J, Han K, Ko S, Ko K, Park C . Trends in the pervasiveness of type 2 diabetes, impaired fasting glucose and co-morbidities during an 8-year-follow-up of nationwide Korean population. Sci Rep. 2017; 7:46656. PMC: 5397969. DOI: 10.1038/srep46656. View

13.

Giugliano R, Cannon C, Blazing M, Nicolau J, Corbalan R, Spinar J . Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017; 137(15):1571-1582. DOI: 10.1161/CIRCULATIONAHA.117.030950. View

14.

Stampfer M, Kang J, Chen J, Cherry R, Grodstein F . Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med. 2005; 352(3):245-53. DOI: 10.1056/NEJMoa041152. View

15.

Wu H, Shang H, Wu J . Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018; 60(2):229-239. DOI: 10.1007/s12020-018-1541-4. View

16.

Hong N, Lee Y, Tsujita K, Gonzalez J, Kramer C, Kovarnik T . Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. Endocrinol Metab (Seoul). 2018; 33(2):219-227. PMC: 6021322. DOI: 10.3803/EnM.2018.33.2.219. View

17.

Lee M, Sun J, Han M, Cho Y, Lee J, Nam C . Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors. Diabetes Care. 2019; 42(11):2057-2064. DOI: 10.2337/dc18-2195. View

18.

Barkas F, Elisaf M, Liberopoulos E, Klouras E, Liamis G, Rizos E . Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol. 2016; 10(2):306-13. DOI: 10.1016/j.jacl.2015.11.015. View

19.

Zafrir B, Jain M . Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther. 2014; 28(4):361-77. DOI: 10.1007/s10557-014-6534-9. View

20.

Lee Y, Han K, Kim B, Lee S, Jun J, Ahn J . Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study. Cardiovasc Diabetol. 2019; 18(1):157. PMC: 6858684. DOI: 10.1186/s12933-019-0953-7. View